ClinicalTrials.gg
RecruitingNCT07847346CAIGISUpdated Oct 2, 2026

China Aortic Infection and Graft Infection Study: An Ambispective Cohort

An observational study in Vascular Graft Infection, Infectious Aortitis and Aortoenteric Fistula, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Shanghai Zhongshan Hospital · Observational

How we know

Updated Oct 2, 2026Title changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

Vascular infections are uncommon but severe infections involving the arterial wall, vascular grafts, or endografts, and their diagnosis and management remain challenging. The CAIGIS Cohort is an ambispective observational cohort established at Zhongshan Hospital, Fudan University, to create an integrated clinical research platform and biobank for patients with suspected or confirmed vascular infections.

The primary research focus is the diagnosis and characterization of causative pathogens. Conventional microbiological methods and emerging molecular diagnostic technologies will be systematically evaluated, with particular emphasis on blood-based pathogen detection as a form of liquid biopsy and its diagnostic value compared with local tissue or operative specimens. Serial blood samples and tissue specimens, when available, will also be used to investigate biomarkers associated with treatment response and clinical outcomes.

Another major focus is the role of molecular imaging, particularly 18F-FDG PET/CT, in the diagnosis and longitudinal assessment of vascular infections. The study will evaluate its diagnostic performance, its added value in patients with inconclusive conventional imaging, and the potential significance of changes in metabolic activity during follow-up for assessing treatment response, residual infection, recurrence, and prognosis.

The cohort will further support nested translational studies addressing specific pathogen- and disease-related questions. These include longitudinal characterization of microbial communities in patients with vascular-enteric fistulas; evaluation of the clinical significance and invasive potential of Candida species; investigation of the clinical and biological characteristics of mycobacterial vascular infections; and exploration of pathogen-host interactions within infected vascular tissues.

By integrating longitudinal clinical data, microbiological results, molecular diagnostics, PET/CT findings, treatment information, outcomes, and biospecimens, the cohort aims to improve etiological diagnosis, disease stratification, treatment monitoring, prognostic assessment, and understanding of the pathogenesis of vascular infections.

Read the detailed description

Vascular infections encompass a heterogeneous group of severe infectious diseases involving the arterial wall, vascular grafts, or endografts, including infectious aortitis, infected arterial aneurysms, vascular graft and endograft infections, and fistula-associated vascular infections. These conditions are associated with substantial morbidity and mortality and remain challenging with respect to etiological diagnosis, assessment of disease activity, therapeutic decision-making, and prediction of recurrence and long-term outcomes.

The CAIGIS Cohort is an ambispective observational cohort established at Zhongshan Hospital, Fudan University. The study is designed as a longitudinal clinical research platform integrating standardized clinical data, microbiological investigations, molecular diagnostics, imaging, treatment information, outcome assessment, and longitudinal biospecimen collection. Patients with suspected or confirmed vascular infections will be included and followed longitudinally. In addition to characterization of the overall disease spectrum, the cohort will serve as a platform for multiple nested diagnostic, prognostic, microbiological, imaging, and translational studies.

Etiological diagnosis and evaluation of diagnostic technologies constitute a major focus of the cohort. Conventional microbiological methods, including blood culture, operative specimen culture, histopathology, and pathogen-specific serological testing, will be evaluated together with emerging molecular diagnostic technologies. Particular attention will be given to blood-based pathogen detection as a form of liquid biopsy, including metagenomic and targeted sequencing approaches where available. Diagnostic yield, incremental diagnostic value, time to etiological diagnosis, concordance between blood and local-site specimens, and the clinical impact of different diagnostic strategies will be investigated. Operative tissue and prosthetic material, when available, will provide an important reference for evaluating blood-based diagnostic approaches.

The cohort will also investigate dynamic biomarkers for disease activity and prognosis. Serial blood samples obtained during diagnosis, treatment, and follow-up may be used to characterize changes in pathogen-derived signals and host-response biomarkers. Their associations with microbiological clearance, treatment response, persistent infection, recurrence, reoperation, and mortality will be explored. The long-term objective is to develop integrated diagnostic and prognostic models combining clinical, microbiological, molecular, imaging, and host-response information.

A further research focus is the role of 18F-FDG PET/CT and other imaging modalities in both diagnosis and longitudinal monitoring. The diagnostic performance and incremental value of PET/CT, particularly in patients with inconclusive conventional imaging, will be evaluated. Where serial PET/CT examinations are clinically available, changes in metabolic activity and imaging patterns will be studied in relation to treatment response, residual infection, recurrence, and prognosis. Quantitative and semi-quantitative imaging parameters may be integrated with microbiological and biomarker data to investigate whether multimodal assessment can improve disease classification and therapeutic monitoring.

Fistula-associated vascular infection, particularly vascular-enteric fistula-associated infection, represents another key area of investigation. These patients often demonstrate complex polymicrobial patterns and may undergo substantial changes in microbial composition during antimicrobial treatment, surgery, and postoperative recovery. Serial blood, operative tissue, fistula-adjacent specimens, and other clinically obtained samples may therefore be used to characterize the longitudinal dynamics of microbial communities, distinguish vascular pathogens from enteric-source organisms, and explore the relationship between microbial composition, fistula status, treatment strategy, and clinical outcome.

The cohort will also support pathogen-specific translational studies. For Candida species, research will focus on distinguishing colonization or contamination from clinically significant invasive vascular infection and identifying microbiological, imaging, host, and clinical features associated with invasive disease and adverse outcomes. For mycobacterial vascular infections, including infections caused by Mycobacterium tuberculosis and nontuberculous mycobacteria, studies will investigate clinical characteristics, diagnostic features, microbial determinants, host susceptibility, and potential mechanisms underlying vascular tropism and persistent infection.

In patients undergoing surgery, infected vascular tissues and prosthetic materials may additionally be used to investigate in situ pathogen-host interactions. These studies may examine the spatial distribution of pathogens within infected tissue, local inflammatory and immune responses, tissue injury, and the relationship between microbial localization and pathological phenotype. Depending on specimen availability and individual nested study protocols, approaches may include microbiological, histopathological, molecular, genomic, transcriptomic, and spatial analyses.

Through the integration of clinical phenotyping, longitudinal biospecimen collection, pathogen-oriented diagnostics, liquid biopsy, molecular imaging, prognostic biomarkers, and translational investigation, the CAIGIS Cohort aims to establish a comprehensive research infrastructure for vascular infections. The overarching goal is to improve etiological diagnosis, disease stratification, treatment monitoring, prognostic assessment, and mechanistic understanding of these complex infections.

02

Conditions studied

  • Vascular Graft Infection
  • Infectious Aortitis
  • Aortoenteric Fistula

Keywords

  • Vascular graft and endograft infection
  • Infectious aneurysm
  • Aortoenteric fistula
  • Metagenomic next-generation sequencing
  • Liquid biopsy
  • 18F-FDG PET/CT
  • Mycobacterium
  • Pathogen-host interaction
  • Microbiome
03

In context

Mycobacterium Infections

59 studies on the registry are indexed under Mycobacterium Infections; 14 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 189 across 26 observational studies indexed under Mycobacterium Infections.

Browse Mycobacterium Infections studies →

Lead sponsor

Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of consecutive adult patients evaluated or treated at Zhongshan Hospital, Fudan University, for suspected or confirmed vascular infections involving the native arterial wall, vascular grafts, or endografts. The cohort includes infectious aortitis, infected arterial aneurysms, vascular graft or endograft infections, and fistula-associated vascular infections. The ambispective design includes retrospectively identified patients with adequate clinical records and prospectively enrolled patients undergoing longitudinal follow-up. Clinical, microbiological, imaging, treatment, and outcome data will be collected, and biospecimens will be retained when available. Final diagnostic classification will be determined by multidisciplinary adjudication integrating clinical presentation, microbiological and molecular findings, imaging, pathology, operative findings, and longitudinal clinical course.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older.
  2. Patients with suspected or confirmed vascular infection involving the native arterial wall, vascular graft, or endograft, including but not limited to infectious aortitis, infected arterial aneurysm, vascular graft or endograft infection, and fistula-associated vascular infection.
  3. Patients evaluated or treated at Zhongshan Hospital, Fudan University, with sufficient clinical information to allow diagnostic adjudication and outcome assessment.
  4. For the prospective cohort, willingness to participate and provide when required.
  5. For the retrospective cohort, availability of relevant clinical records meeting the requirements approved by the institutional ethics committee.

Exclusion criteria

Exclusion Criteria:

  1. Isolated superficial surgical-site infection without evidence of involvement of the arterial wall, vascular graft, or endograft.
  2. Insufficient clinical data to permit diagnostic adjudication or longitudinal outcome assessment.
  3. Refusal to participate in the prospective component when is required.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients With Vascular Infections

    Patients with suspected or confirmed vascular infections, including infectious aortitis, infected arterial aneurysms, vascular graft or endograft infections, and fistula-associated vascular infections. Clinical, microbiological, molecular diagnostic, imaging, treatment, outcome, and biospecimen data will be collected longitudinally to support diagnostic, prognostic, and translational studies.

06

What researchers measure

Primary outcomes

  1. Sustained Cure Rate One Year After Discontinuation of Antimicrobial Therapy

    Proportion of participants who remain alive and free from persistent or recurrent vascular infection for 1 year after discontinuation of antimicrobial therapy, without reinitiation of antimicrobial treatment for the index vascular infection or unplanned infection-related surgical or endovascular intervention.

    Time frame: 1 year after discontinuation of antimicrobial therapy

  2. Five-Year All-Cause Mortality

    Proportion of participants who die from any cause within 5 years after the index diagnosis of vascular infection.

    Time frame: 5 years after the index diagnosis

Secondary outcomes

  1. Proportion of Patients Requiring Lifelong Suppressive Antimicrobial Therapy

    Proportion of participants requiring indefinite or lifelong suppressive antimicrobial therapy because complete eradication of vascular infection is not considered achievable. The proportion will be assessed separately among patients managed conservatively and those undergoing surgical or endovascular treatment.

    Time frame: Up to 2 years after diagnosis

  2. Five-Year Infection-Related Mortality

    Percentage of participants who die from causes directly or indirectly attributable to the index vascular infection within 5 years after the index diagnosis. Infection-related death will be determined by multidisciplinary clinical adjudication based on the clinical course, microbiological findings, imaging, operative findings, and documented cause of death.

    Time frame: Up to 5 years after the index diagnosis

Other outcomes

  1. Incremental Diagnostic Yield of Individual Diagnostic Technologies

    Proportion of participants in whom an additional etiological diagnosis is established by a specific diagnostic modality beyond conventional microbiological evaluation. Incremental diagnostic yield will be assessed separately for blood-based molecular diagnostics, including liquid biopsy approaches, serological testing, molecular testing of local or operative specimens, and other advanced diagnostic methods where available.

    Time frame: Within 90 days after the index diagnosis

  2. Rate of Diagnostic Test-Related Changes in Clinical Management

    Rate of Diagnostic Test-Related Changes in Clinical Management

    Time frame: From enrollment to 90 days after the index diagnosis

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Linder KA, Miceli MH. Impact of Metagenomic Next-Generation Sequencing of Plasma Cell-free DNA Testing in the Management of Patients With Suspected Infectious Diseases. Open Forum Infect Dis. 2023 Jul 24;10(8):ofad385. doi: 10.1093/ofid/ofad385. eCollection 2023 Aug. PubMed 37601730 ↗
  • Lauri C, Signore A, Glaudemans AWJM, Treglia G, Gheysens O, Slart RHJA, Iezzi R, Prakken NHJ, Debus ES, Honig S, Lejay A, Chakfe N. Evidence-based guideline of the European Association of Nuclear Medicine (EANM) on imaging infection in vascular grafts. Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3430-3451. doi: 10.1007/s00259-022-05769-x. Epub 2022 Apr 4. PubMed 35376992 ↗
  • Husmann L, Sah BR, Scherrer A, Burger IA, Stolzmann P, Weber R, Rancic Z, Mayer D, Hasse B; VASGRA Cohort. (1)(8)F-FDG PET/CT for Therapy Control in Vascular Graft Infections: A First Feasibility Study. J Nucl Med. 2015 Jul;56(7):1024-9. doi: 10.2967/jnumed.115.156265. Epub 2015 May 14. PubMed 25977463 ↗
  • Ajdler-Schaeffler E, Scherrer AU, Keller PM, Anagnostopoulos A, Hofmann M, Rancic Z, Zinkernagel AS, Bloemberg GV, Hasse BK; and the VASGRA Cohort. Increased Pathogen Identification in Vascular Graft Infections by the Combined Use of Tissue Cultures and 16S rRNA Gene Polymerase Chain Reaction. Front Med (Lausanne). 2018 Jun 4;5:169. doi: 10.3389/fmed.2018.00169. eCollection 2018. PubMed 29915786 ↗
  • Anagnostopoulos A, Mayer F, Ledergerber B, Bergada-Pijuan J, Husmann L, Mestres CA, Rancic Z, Hasse B; VASGRA Cohort Study. Editor's Choice - Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endograft Infection: Results from the Prospective Vascular Graft Cohort Study. Eur J Vasc Endovasc Surg. 2021 Aug;62(2):251-257. doi: 10.1016/j.ejvs.2021.05.010. Epub 2021 Jun 14. PubMed 34140225 ↗
  • Lyons OT, Baguneid M, Barwick TD, Bell RE, Foster N, Homer-Vanniasinkam S, Hopkins S, Hussain A, Katsanos K, Modarai B, Sandoe JA, Thomas S, Price NM. Diagnosis of Aortic Graft Infection: A Case Definition by the Management of Aortic Graft Infection Collaboration (MAGIC). Eur J Vasc Endovasc Surg. 2016 Dec;52(6):758-763. doi: 10.1016/j.ejvs.2016.09.007. Epub 2016 Oct 19. PubMed 27771318 ↗
  • Sorelius K, Verhoek R, Berard X, Lyons OTA, Puges M, Wyss TR; International Expert Panel on Vascular Graft and Endograft Infections; European Society for Vascular Surgery Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections Writing Committee. Vascular Graft and Endograft Infections: A Delphi Consensus Document on Terminology, Definitions, Treatment, Outcomes, Follow Up, and Reporting Standards. Eur J Vasc Endovasc Surg. 2026 Mar;71(3):497-507. doi: 10.1016/j.ejvs.2025.07.044. Epub 2025 Jul 29. PubMed 40744353 ↗
  • Lejay A, Saleem BR, Barwick TD, Beck AW, Berard X, Eilenberg W, Gavali H, Hasse B, Heinola I, Lyons OT, Perini P, Puges M, Price NM, Sorelius K, Wouthuyzen-Bakker M, Wyss TR, Boyle J, Dias NV, van Herzeele I, Lepidi S, Mees BME, Resch T, Ribeiro TF, Trimarchi S, Wanhainen A, Chakfe N, Hernandez-Meneses M, Kahlberg A, Khashram M, Szeberin Z, Zeebregts C. Editor's Choice - European Society for Vascular Surgery (ESVS) 2026 Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections. Eur J Vasc Endovasc Surg. 2026 Aug;72(2):227-293. doi: 10.1016/j.ejvs.2026.05.035. Epub 2026 Jul 14. PubMed 42448560 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in peer-reviewed publications may be shared upon reasonable request. Data sharing will be subject to approval by the study investigators and relevant institutional or ethics committees, and will comply with applicable privacy, data protection, and regulatory requirements. Data containing potentially identifiable, genomic, or other sensitive information may be subject to additional restrictions.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 12 months after publication of the main study results and available for 5 years.

Access criteria: Researchers may submit a scientifically sound proposal to the principal investigator. Requests will be reviewed based on scientific merit, feasibility, participant privacy, ethical approval, and applicable institutional and regulatory requirements. Approved researchers may be required to sign a data use agreement before access is granted.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2036, 120 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2036
CompletionEst.
Nov 1, 2041
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
China Aortic Infection and Graft Infection Study: An Ambispective Cohort Study in China
Oct 2, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Oct 2, 2026
    Title China Aortic Infection and Graft Infection Study: An Ambispective Cohort Study in China
    + 1 other change: description
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847346
Responsible party
Qing Miao (Associate Chief Physician, Shanghai Zhongshan Hospital) — Principal investigator
First posted
Sep 29, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2036 (estimated)
Completion
Nov 1, 2041 (estimated)
Last update
Oct 2, 2026

Study contacts

Qing Miao, MD, PhD
Contact
miao.qing@zs-hospital.sh.cn
+8613917763967
Jianing Yue, MD, PhD
Contact
yuejianing@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion